Further pharmacological evaluation of a novel synthetic peptide bradykinin B2 receptor agonist.
We recently identified a novel human B2 receptor (B2R) agonist [Hyp(3),Thi(5),(N)Chg(7),Thi(8)]-bradykinin (NG291) with greater in vitro and in vivo potency and duration of action than natural bradykinin (BK). Here, we further examined its stability and selectivity toward B2R. The hypotensive, antithrombotic, and profibrinolytic functions of NG291 relative to BK and its analogue ([Hyp(3),Thi(5),(4-Me)Tyr(8)(ΨCH(2)NH)Arg(9)]-BK) (RMP-7) were also tested. Contraction assays using isolated mouse stomachs (containing kinin B1R, B2R, and kininase I- and II-like activities) showed that NG291 is a more potent contractant than BK and is inhibited by HOE-140 (B2R antagonist) but unaffected by R954 (B1R antagonist), whereas both decreased the potency of BK. In stomach tissues from B2R knockout mice, BK maintained its activity via B1R, whereas NG291 had no contractile effect, indicating that it was selective for B2R. Unlike BK, NG291 was not degraded by rabbit lung ACE. Comparing intravenously administered BK and NG291 revealed that NG291 exhibited more potent and prolonged hypotensive action and greater antithrombotic and profibrinolytic activities. These effects were of comparable magnitude to RMP-7 and were absent in B2R knockout mice. We concluded that NG291 is a novel biostable B2R-selective agonist that may prove suitable for investigating the (pre)clinical cardioprotective efficacy of B2R activation.
Faculty of Medicine and Health Sciences, Department of Pharmacology, Institute of Pharmacology, Universite de Sherbrooke, Sherbrooke, QC, J1H 5N4 Canada.
Martin
M
Savard
Julie
J
Labonté
Céléna
C
Dubuc
Witold
W
Neugebauer
Pedro
P
D'Orléans-Juste
Fernand
F
Gobeil
D000818:Animals; D060326:Chemistry Techniques, Synthetic; D005343:Fibrinolytic Agents / Q000494:pharmacology; D051379:Mice; D018345:Mice, Knockout; D009119:Muscle Contraction / Q000187:drug effects*; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology*; D057786:Peptidomimetics; D011485:Protein Binding / Q000187:drug effects; D043782:Receptor, Bradykinin B2 / Q000819:agonists*
D005343:Fibrinolytic Agents; D010455:Peptides; D057786:Peptidomimetics; D043782:Receptor, Bradykinin B2